Ali Zandieh, MD
Neurology · Madison, WINPI 1518320126
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $343 of the $418 with a category attached, or 82.1%. 3 manufacturers reported payments, led by Sanofi at 59.2% of the total.
Across 4 payments — averaging $104.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$248
- Amgen$95
- Sanofi-aventis U.S. LLC$75
Across 27 payments — averaging $4149.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$112K
What the payments were for
- Food & beverage$34382%
- Education$7518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 2 | $248 |
| Amgen | 1 | $95 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$125
- AUBAGIO$123
How this compares
$418 in reported general payments places this provider in the 60th percentile of 308 neurology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 132 | $99,609 |
| Nurtec OdtRimegepant Sulfate | 51 | $94,829 |
| UbrelvyUbrogepant | 63 | $64,112 |
| QuliptaAtogepant | 22 | $26,344 |
| Aimovig AutoinjectorErenumab-Aooe | 19 | $19,439 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 19 | $17,036 |
| ReyvowLasmiditan Succinate | 13 | $7,539 |
| Sumatriptan Succinate | 18 | $4,205 |
| Levetiracetam | 58 | $3,964 |
| Gabapentin | 113 | $1,907 |
| Pregabalin | 88 | $1,868 |
| Zolmitriptan | 18 | $1,622 |
| Divalproex Sodium | 11 | $1,467 |
| Cyclobenzaprine Hcl | 13 | $1,239 |
| Carbamazepine | 16 | $1,125 |
Paid to pharmacies, not to this prescriber.
Other neurology in Madison
- Michael SnyderMadison$284K
- Kelsey GageschMadison$60K
- Brian NagleMadison$25K
- Michael FruchtMadison$22K
- Vanesa BotsfordMadison$11K
- Amanda AbuafMadison$11K
- Christopher LuzzioMadison$9K
- Ankush BhatiaMadison$7K
- Rama MagantiMadison$6K
- Elizabeth FeltonMadison$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.